Retatrutide (Retatrutide (Triple Agonist GIP/GLP-1/Glucagon))
A novel triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 shows unprecedented 24% body weight loss at 48 weeks.
How it works
Triple agonism creates synergistic metabolic effects. Glucagon activation increases energy expenditure and hepatic fat oxidation while GLP-1/GIP reduce appetite and improve insulin sensitivity.
Key facts
- Molecular weight: 5,200 Da (approximate)
- Half-life: 6 days
- Bioavailability: High (SubQ)
- Storage: Refrigerated 2-8°C.
Dosing overview
- Typical dose: 1-2 mg → titrate up to 12 mg
- Frequency: Once weekly
- Duration: Ongoing (investigational)
- Route: Subcutaneous injection
Protocol notes
- Trials start around 1-2 mg weekly and escalate monthly.
- Step up gradually toward 4, 8, then 12 mg; 12 mg showed maximum weight loss in Phase 2.
- Hold at the lowest dose giving the desired appetite/weight response.
Reported benefits
- Unprecedented weight loss (~24%)
- Significant liver fat reduction
- Improved cardiovascular markers
- Enhanced energy expenditure
- Superior glycemic control
Possible side effects
- GI effects (nausea, diarrhea, vomiting)
- Decreased appetite
- Heart rate increase
Research
- Phase 2 trial of retatrutide for obesity (2023): At 48 weeks, retatrutide 12mg achieved 24.2% mean weight loss with 26% losing 30%+ body weight.
- Retatrutide effects on hepatic steatosis (2023): Reduced liver fat by 81-86% with complete resolution of steatosis in up to 90% of participants.
Compare Retatrutide
Community discussions about Retatrutide
- Limited-Time Promotion - 0 comments
- Factory Direct With Full After‑Sales Protection - 3 comments
- Teens on retatrutide from social media is exactly what keeps me up at night - 6 comments
- China Peptide Source Factory - 3 comments
- Retatrutide Research Peptide and the Importance of Reliable Research Data - 8 comments
- Ask the community about Retatrutide
Research and educational reference only. Not medical advice.